EYPT
NEUTRAL
$14.17
Live
EyePoint, Inc. · NASDAQ
Target $37.42
(+164.1%)
$4.15
52W Range
$19.11
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 09, 2026
Market cap
$1.18B
P/E
N/A
ROE
-72.2%
Profit margin
N/A
Debt/Equity
0.47
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
90%
EYPT shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 0/9). Mixed signals with both opportunities and risks present.
Key Strengths
Strong revenue growth of 161.7%
Low debt with D/E ratio of 0.47
Key Risks
Weak financial trend (Piotroski F-Score: 0/9)
Weak ROE of -72.2%
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
38
Weak
50
65
40
35
0
AI Verdict
EYPT shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 0/9). Mixed signals with both opportunities and risks present.
Key drivers: Strong revenue growth of 161.7%, Low debt with D/E ratio of 0.47, Weak financial trend (Piotroski F-Score: 0/9)
Confidence
50%
Value
50/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Future
65/100
Rule-based growth outlook.
Positives
- Revenue growth running at 161.7%.
Watchpoints
No urgent risks highlighted.
Past
40/100
Historical performance + price trend: Shares moved +41.6% over 5Y and +243.1% over 1Y.
Positives
- Insufficient data for clear positives.
Watchpoints
- ROE only -72.2%.
Health
35/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Low D/E ratio (0.47).
Watchpoints
No urgent risks highlighted.
Dividend
0/100
Dividend policy fallback.
Positives
- Insufficient data for clear positives.
Watchpoints
- No regular dividend payments.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$14.17
Analyst Target
$37.42
Upside/Downside
+164.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for EYPT and closest competitors.
Updated 2026-04-08
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
EYPT
EyePoint, Inc.
Primary
|
+41.6% | +326.8% | +243.1% | +2.1% | -9.6% | +8.8% |
|
ALVO
Alvotech
Peer
|
-65.9% | -71.8% | -66.2% | -52.0% | -17.7% | -1.6% |
|
BLFS
BioLife Solutions, Inc.
Peer
|
-40.8% | -0.5% | -10.7% | +10.1% | -2.1% | +1.8% |
|
BFLY
Butterfly Network, Inc.
Peer
|
-76.9% | +59.4% | +8.9% | +128.9% | +14.2% | +8.4% |
|
ABCL
AbCellera Biologics Inc.
Peer
|
-90.7% | -53.9% | +45.4% | -21.9% | +11.5% | +1.2% |
EYP
EyePoint, Inc.
Primary
5Y
+41.6%
3Y
+326.8%
1Y
+243.1%
6M
+2.1%
1M
-9.6%
1W
+8.8%
ALV
Alvotech
Peer
5Y
-65.9%
3Y
-71.8%
1Y
-66.2%
6M
-52.0%
1M
-17.7%
1W
-1.6%
BLF
BioLife Solutions, Inc.
Peer
5Y
-40.8%
3Y
-0.5%
1Y
-10.7%
6M
+10.1%
1M
-2.1%
1W
+1.8%
BFL
Butterfly Network, Inc.
Peer
5Y
-76.9%
3Y
+59.4%
1Y
+8.9%
6M
+128.9%
1M
+14.2%
1W
+8.4%
ABC
AbCellera Biologics Inc.
Peer
5Y
-90.7%
3Y
-53.9%
1Y
+45.4%
6M
-21.9%
1M
+11.5%
1W
+1.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-5.16
PEG Ratio
N/A
P/B Ratio
3.83
P/S Ratio
37.69
EV/Revenue
42.0
EV/EBITDA
-5.46
Market Cap
$1.18B
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-450.65%
Gross Margin
N/A
ROE
-72.19%
ROA
-38.89%
Growth
Revenue and earnings growth rates
Revenue Growth
+161.7%
Earnings Growth
N/A
Q/Q Revenue Growth
-94.65%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.47
Low debt
Current Ratio
8.88
Strong
Quick Ratio
8.29
Excellent
Cash/Share
$0.48
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
39.5%
Op. Margin
-11346.0%
Net Margin
-10904.7%
Total Assets
$0.4B
Liabilities
$0.1B
Equity
$0.3B
Debt/Equity
0.19x
Operating CF
$-0.1B
CapEx
$-0.0B
Free Cash Flow
$-0.1B
FCF Yield
102%
Healthcare Sector Comparison
Comparing EYPT against 189 companies in the Healthcare sector
(17 bullish, 63 neutral, 109 bearish)
Return on Equity (ROE)
-72.19%
This Stock
vs
-44.08%
Sector Avg
+63.8%
(Excellent)
Debt to Equity
0.47
This Stock
vs
5.1
Sector Avg
-90.8%
(Less Debt)
Revenue Growth
161.7%
This Stock
vs
108.17%
Sector Avg
+49.5%
(Fast Growth)
Current Ratio
8.88
This Stock
vs
3.39
Sector Avg
+161.8%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
EYPT
EyePoint, Inc.
|
NEUTRAL | $1.18B | - | -72.2% | -% | $14.17 | |
|
ALVO
Alvotech
|
BEARISH | $1.19B | 16.61 | -% | 12.1% | $3.82 | Compare |
|
BLFS
BioLife Solutions, Inc.
|
NEUTRAL | $1.2B | - | -5.2% | -3.2% | $24.87 | Compare |
|
BFLY
Butterfly Network, Inc.
|
NEUTRAL | $1.14B | - | -41.4% | -90.3% | $4.51 | Compare |
|
ABCL
AbCellera Biologics Inc.
|
NEUTRAL | $1.06B | - | -14.5% | -194.9% | $3.49 | Compare |
EYPT
EyePoint, Inc.
NEUTRAL
Mkt Cap
$1.2B
P/E
-
ROE
-72.2%
Price
$14.17
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-16 | DUKER JAY S | Chief Executive Officer | Purchase | 1,500 | $19,724 |
| 2026-03-04 | RIBEIRO RAMIRO | Officer | Sale | 2,438 | $43,572 |
| 2026-03-04 | RIBEIRO RAMIRO | Officer | Option Exercise | 2,438 | $20,138 |
| 2026-03-02 | ELSTON GEORGE O | Chief Financial Officer | Gift | 5,000 | - |
| 2026-02-17 | RIBEIRO RAMIRO | Officer | Sale | 2,437 | $36,555 |
| 2026-02-17 | RIBEIRO RAMIRO | Officer | Option Exercise | 2,437 | $20,130 |
| 2026-01-06 | ELSTON GEORGE O | Chief Financial Officer | Stock Award | 15,285 | - |
| 2026-01-06 | LURKER NANCY S | Director | Stock Award | 75,133 | - |
| 2026-01-06 | DUKER JAY S | Chief Executive Officer | Stock Award | 20,793 | - |
| 2026-01-05 | ELSTON GEORGE O | Chief Financial Officer | Stock Award | 34,667 | - |
| 2026-01-05 | LURKER NANCY S | Director | Stock Award | 12,666 | - |
| 2026-01-05 | DUKER JAY S | Chief Executive Officer | Stock Award | 95,000 | - |
| 2026-01-05 | RIBEIRO RAMIRO | Officer | Sale | 42,544 | $727,319 |
| 2026-01-05 | RIBEIRO RAMIRO | Officer | Option Exercise | 29,250 | $241,605 |
| 2026-01-02 | RIBEIRO RAMIRO | Officer | Stock Award | 19,667 | - |
DUKER JAY S
Chief Executive Officer
2026-03-16
1,500 shares
·
$19,724
RIBEIRO RAMIRO
Officer
2026-03-04
2,438 shares
·
$43,572
RIBEIRO RAMIRO
Officer
2026-03-04
2,438 shares
·
$20,138
ELSTON GEORGE O
Chief Financial Officer
2026-03-02
5,000 shares
RIBEIRO RAMIRO
Officer
2026-02-17
2,437 shares
·
$36,555
RIBEIRO RAMIRO
Officer
2026-02-17
2,437 shares
·
$20,130
ELSTON GEORGE O
Chief Financial Officer
2026-01-06
15,285 shares
LURKER NANCY S
Director
2026-01-06
75,133 shares
DUKER JAY S
Chief Executive Officer
2026-01-06
20,793 shares
ELSTON GEORGE O
Chief Financial Officer
2026-01-05
34,667 shares
LURKER NANCY S
Director
2026-01-05
12,666 shares
DUKER JAY S
Chief Executive Officer
2026-01-05
95,000 shares
RIBEIRO RAMIRO
Officer
2026-01-05
42,544 shares
·
$727,319
RIBEIRO RAMIRO
Officer
2026-01-05
29,250 shares
·
$241,605
RIBEIRO RAMIRO
Officer
2026-01-02
19,667 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
12 analysts
Citigroup
2026-03-09
Buy
Buy
HC Wainwright & Co.
2026-03-05
Buy
Buy
Chardan Capital
2026-03-04
Buy
Buy
RBC Capital
2025-11-06
Outperform
Outperform
Past News Coverage
Recent headlines mentioning EYPT from our newsroom.
Newest → oldest
No matching news yet.